In line, several CD73 blocking antibodies and small molecules are currently under clinical development for the treatment of cancer, mostly as part of combination therapies (see, e.g., www.clinicaltrials.gov, accessed on 21 February 2022). The gene discussed is NT5E; the disease is cancer.